Fung Ethan

Dr. Fung Ethan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
FEFung Ethan
Fung Ethan
KMKeisha E. Montalmant
Keisha E. Montalmant
JRJacquelyn M. Roth
Jacquelyn M. Roth
MGMaxwell Godek
Maxwell Godek
JLJian H. Li
Jian H. Li
PHPeter W. Henderson
Peter W. Henderson

12 March 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
FEFung Ethan
Fung Ethan
MGMaxwell Godek
Maxwell Godek
JRJacquelyn M. Roth
Jacquelyn M. Roth
KMKeisha E. Montalmant
Keisha E. Montalmant
BYBernice Z. Yu
Bernice Z. Yu
PHPeter William Henderson
Peter William Henderson

1 August 2022 in Journal of Experimental Psychology: General
Verified
Journal Article
Closed access
SCSantiago Castiello
Santiago Castiello
RMRalph R. Miller
Ralph R. Miller
JWJames E. Witnauer
James E. Witnauer
DADoriann M. Alcaide
Doriann M. Alcaide
FEFung Ethan
Fung Ethan
RMRobin A. Murphy
Robin A. Murphy
The statistical relation between two events influences the perception of how one event relates to the presence or absence of another. Interestingly, the simultaneous absence of both events, just like their mutual occurrence, is relevant for describing their contingency. In three experiments, we explored the relevance of coabsent events by varying the duration and frequency of trials without stimuli. We used a rapid trial streaming procedure and found that the perceived association between events is enhanced with increasing frequency of coabsent events, unlike the duration of coabsent events, which had little effect. These findings suggest ways in which the benefits of trial spacing, during which both events are absent, could be obtained without increasing total training time. Centrally, this can be done by frequent repeating of shortened coabsent events, each marked by a trial contextual cue. We discuss four potential accounts of how coabsent experience might be processed contributing to this effect: (a) contingency sensitivity, (b) testing effect, (c) reduced associative interference by the context, and (d) reduced encoding interference. (PsycInfo Database Record (c) 2022 APA, all rights reserved).

24 August 2023 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
FEFung Ethan
Fung Ethan
PCPriscila Cevallos
Priscila Cevallos
KTKometh Thawanyarat
Kometh Thawanyarat
MRMallory Rowley
Mallory Rowley
YNYelissa Navarro
Yelissa Navarro
RNRahim Nazerali
Rahim Nazerali

7 October 2022 in Cureus
Verified
Journal Article
Open access
MGMitchell R. Gore
Mitchell R. Gore
FEFung Ethan
Fung Ethan
MTMichael Tao
Michael Tao
Asthma, Allergic rhinitis (AR), Chronic Obstructive Pulmonary Disease (COPD), Eczema, and Chronic Rhinosinusitis with Sinonasal Polyposis (CRSwNP) are illnesses often characterized by type 2 (T2) inflammation, wherein T helper (Th) cells release pro-inflammatory cytokines such as IL (interleukin)-4, IL-5, IL-9, and IL-13. This response may also promote the production of IgE and an increase in/activation of serum eosinophils. In the aforementioned type 2 inflammatory diseases, this immune response can cause excess mucous production, inflammation of the airways, other atopic responses when patients are exposed to certain environmental allergic triggers. Relatively new biologic monoclonal antibody therapies such as dupilumab (blocks IL-4 and IL-13), benralizumab (blocks IL-5), mepolizumab (blocks IL-5), and omalizumab (blocks IgE Fc/fragment of crystallization region) offer novel therapeutic targets that more specifically and directly block type 2 inflammatory responses. To examine the effect of monoclonal antibody biologic therapies on patient indicators of type 2 inflammation, a retrospective analysis of 193 patients on biologic therapy was conducted, and these patients were compared to 48 control patients with type 2 inflammatory diseases who did not initiate biologic therapy. Total Lund-MacKay radiographic score, FEV1 (forced expiratory volume in the first second), FEF25-75 (forced expiratory flow from 25-75% of the forced vital capacity curve), annualized pulmonary exacerbations, oral corticosteroid dose, and serum eosinophils were recorded at baseline (zero months), and at three, six, nine, and twelve months after initiation of biologic therapy. Least squares mean data and the percent change from the baseline of least squares mean for the biologic and control groups were compared. Omalizumab was the most common biologic therapy prescribed. Control patients were younger than patients who initiated biologic therapy. Patients on biologic therapy had statistically significant reductions in Lund-MacKay score, improvements in FEV1 and FEF25-75, reductions in serum IgE levels, and reductions in serum Eosinophils. Patients on biologic therapy also had statistically significant reductions in annualized pulmonary exacerbations and oral corticosteroid dose compared to controls. Patients with a variety of type 2 inflammatory conditions appear to have significant improvements in lung function, radiographic sinusitis, and serum markers of type 2 inflammation after initiation of biologic therapy versus controls. These therapeutic medications appear to significantly improve type 2 inflammatory disease course in patients who can tolerate these medications.

12 August 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
FEFung Ethan
Fung Ethan
JRJacquelyn Roth
Jacquelyn Roth
DSDiana S. Shaari
Diana S. Shaari
BYBernice Z. Yu
Bernice Z. Yu
PTPeter J. Taub
Peter J. Taub